Arbutus Biopharma Corp (ABUS) Stock AnalysisABUSArbutus Biopharma Corp

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arbutus Biopharma Corp. (ABUS) is a good buy right now due to its recent positive developments, including a significant $230 million share buyback plan and the lifting of the FDA clinical hold on its AB-101 treatment. The company's current price is $4.20, and it has a forward P/E ratio of 10.25, suggesting it is undervalued compared to its earnings potential. However, it has experienced a 20-day change of -13.40%, indicating some volatility that investors should consider.

7 analysts cover ABUS: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 7.00.